



Oral Communications

Friday, May 27th 2022

8:30 – 10:45 Plenary Session 1: Emerging trends in cancer associated thrombosis

Chairs: **Per Morten Sandset (Norway), Rita Selby (Canada)**

OC-01: Mortality impact of cancer-associated venous thromboembolism: Final analysis from Oncothromb12-01 study

M. Ruiz, A. Muñoz, C. Font, V. Castellón, M. Salgado, E. Martínez, A. Rupérez, A. Cárdenas, R. Martín-Lozano, I. González-Caraballo, R. Jiménez, L. Ortega, E. Salas, J.M Soria (Spain)

OC-02: Outcomes of cancer-associated isolated superficial vein thrombosis in daily practice

F. Langer, H.E. Gerlach, A. Schimke, A. Heinken, U. Hoffmann, T. Noppeney, D. Pittrow, J. Klotzsche, E. Rabe, R. Bauersachs (Germany)

11:15 – 13:30 Plenary Session 2: Exploring the relationship between hemostasis and cancer: New insights

Chairs: **Anne-Karin Olsson (Sweden), Raffaella Giavazzi (Italy)**

OC-03: Platelet-derived von Willebrand factor is involved in thrombosis and metastatic growth of melanoma in the brain

S.W. Schneider, J.R. Robador, F. T. Mayer, M. Feinauer, L. Keller, K. Pantel, J. Stadler, C. Gorzelanny, F. Winkler, and A.T. Bauer (Germany)

OC-04: Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress

J. Cedervall, M. Herre, A. Dragomir, F. Rabelo-Melo, A. Svensson, C. Thålin, A. Rosell, V. Hjalmar, H. Wallén, H. Lindman, G. Pejler, E. Hagström, M. Hultström, A. Larsson, A.K. Olsson (Sweden)

15:00 – 17:30 Plenary Session 3: Role of hemostatic biomarkers in CAT and cancer progression

Chairs: **Cihan Ay (Austria), Fionnuala Ní Áinle (Ireland)**

OC-05: Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis

R.J.S. Anijis, Q. Chen, W.M. Lijfering, S.C. Cannegieter (The Netherlands)

OC-06: Identification of predictive hemostatic biomarkers for cancer diagnosis: results from the HYPERCAN study

S. Gamba, M. Marchetti, L. Russo, C. Giaccherini, S. Bolognini, C. J. Tartari, C. Verzeroli, C. Ticozzi, A. Vignoli, F. Schieppati, G. Sampietro, P. Malighetti, D. Spinelli, and A. Falanga (Italy)

OC-07: Contact pathway activation and risk of venous thromboembolism in patients with pancreatic cancer: the prospective SENECA study

F.T.M. Bosch, E. Campello, M.W. Henderson, F.I. Mulder, S. Gavasso, C. Bassi, J.W. Wilink, H.M. Otten, N. van Es, A. Ilich, N. Key, H.R. Büller, P. Simioni (The Netherlands, USA, Italy)



Saturday, May 28th 2022

8:30 – 10:45 Plenary session 4: Hemostatic complications and novel anti-cancer therapies

Chairs: Ilene Weitz (USA), Wolfram Ruf (Germany)

OC-08: The Khorana score and risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors

T.F. Overvad, A.G. Ording, P.B. Nielsen, G. Piazza, S. Noble⁵, T.B. Larsen, F. Skjøth (UK)

OC-09: Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomized controlled trial

C.C. Kirwan, J. Castle, S.A. Pritchard, N.J. Bundred, J. Thachill, J.R. Harvey, P.G. Roy, A. Volleamere, E. Blower, C. Palmieri, B. Hogan, R. Vinayagam, K. Cox, A. Marshall, L. Turner, G. Gibson, H. Scott, C. Holcombe (UK)

11:15 – 13:30 Plenary Session 5: COVID-19, thrombosis, and cancer

Chairs: Valerio De Stefano (Italy), Howard A. Liebman (USA)

OC-10: Plasmatic von Willebrand factor encapsulates blood circulating melanoma cells to prevent their hematogenous metastasis

Y. Wang, X. Liu, T. Obser, A.T. Bauer, M. Kusche-Gullberg, S. W. Schneider, C. Gorzelanny (Norway)

OC-11: Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study

Z. Sayar, C. Gates, S. Bristogiannis, A. Patel, M.O. Ogunbiyi, A. Tailor, K. Yong, M. Thomas (UK)



Sunday, May 29th 2022

8:30 – 10:45 Plenary Session 6: Cardiovascular complications in cancer patients

Chairs: **Pantep Angchaisuksiri (Thailand), Bianca Rocca (Italy)**

OC-12: Stroke and Risk of Cancer: A Danish Population-based Cohort Study

N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. Sørensen (Denmark)

OC-13: Differentially expressed coagulome genes (DECGs) are prognostic in breast cancer

M. Tinholt, X. Tekpli, V. Kristensen, P.M. Sandset, N. Iversen (Norway)

12:45 – 15:30 Plenary 7: Prevention and treatment of Cancer-Associated Thromboembolism

Chairs: **Roberto Labianca (Italy), Annie Young (UK)**

OC-14: Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study

M. Monreal, L. Bertoletti, J. J. López-Núñez, G. Tiberio, S. Soler, C. Gómez-Cuervo, Á. Fidalgo, M. Mellado, P. López-Miguel, J. A. Díaz-Peromingo, and the RIETE Investigators (France, Spain)

OC-15: Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers (TARGET-TP); a randomized trial

M. Alexander, S.J. Harris, C. Underhill, J.T. orres, S.Sharma, N. Lee, H. Wong, R. Eek, M. Michael, J. Tie, J. Rogers, A. Heriot, D. Ball, M. MacManus, R. Wolfe, B. Solomon, K. Burbury (Australia)

OC-16: Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types considered to have high and low risks of bleeding, receiving DOACs or LMWH – The OSCAR UK Study

A.T. Cohen, C. Wallenhorst, C. Ay, B. Schaefer, K. Abdelgawwad, G. Psaroudakis, G. Brobert, C. I. Coleman, A. Ekbom, A.Y.Y. Lee, A. Khorana, C. Becattini, M. Carrier, M. Rivera, C. Martinez (UK, Germany, USA, Sweden, Canada)